Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript
Summarize this article with:
SA Transcripts159.47K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 April 27, 2026 4:30 PM EDT Company Participants Jonathan Lim - Co-Founder, Chairman & CEOShannon Morris - Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research DivisionMaurice Raycroft - Jefferies LLC, Research DivisionJonathan Miller - Evercore ISI Institutional Equities, Research DivisionLaura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research DivisionMichael Schmidt - Guggenheim Securities, LLC, Research DivisionSean Laaman - Morgan Stanley, Research DivisionKelsey Goodwin - Piper Sandler & Co., Research DivisionJoseph Catanzaro - Mizuho Securities USA LLC, Research DivisionAlec Stranahan - BofA Securities, Research Division Presentation Operator Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman. Please go ahead. Jonathan LimCo-Founder, Chairman & CEO Welcome to Erasca's ERAS-0015 preliminary Phase I data update. We are excited to share these data with you and appreciate you joining us today. Here with me are David Chacko, our CFO and Chief Business Officer; Shannon Morris, our Chief Medical Officer; Robert Shoemaker, our Chief Scientific Officer; and Dawei Xuan, our SVP of Clinical Pharmacology. Please note that we will be making forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We will also be making comparisons and pooling of clinical data across separate non-head-to-head studies and caution should be exercised when drawing conclusions from such data as such data may not be directly comparable. Please see the cautionary language included on the disclaimer slide of this presentation and in our latest SEC filings and the risk factors associated with our business. In addition, any statements made today represent our views only as of the date of this